Comparative effectiveness studies to improve clinical outcomes in end stage renal disease: The DEcIDE patient outcomes in end stage renal disease study

BMC Nephrology

Volumn 13, Issue 1, 2012, Pages

  Boulware, Ebony L ^a,b,d   Tangri, Navdeep ^c   Ephraim, Patti L ^a,d   Scialla, Julia J ^e   Sozio, Stephen M ^a,b   Crews, Deidra C ^a,b   Shafi, Tariq ^a,b   Miskulin, Dana C ^f   Liu, Jiannong ^g   St Peter, Wendy ^g,h   Jaar, Bernard G ^a,b,d,i   Wu, Albert W ^b,d   Powe, Neil R ^j   Navaneethan, Sankar D ^k   Bandeen Roche, Karen ^d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^h UNIVERSITY OF MINNESOTA   (United States)

ⁱ NEPHROLOGY CENTER OF MARYLAND   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k LERNER RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; IRON;

ANTIHYPERTENSIVE THERAPY; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; DIALYSIS; HEMODIALYSIS PATIENT; HUMAN; IRON THERAPY; KIDNEY FAILURE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PROPENSITY SCORE; QUALITY OF LIFE; STATISTICAL MODEL; STUDY DESIGN; SYSTEMATIC ERROR; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; IRON; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PREVALENCE; QUALITY IMPROVEMENT; REGISTRIES; RENAL DIALYSIS; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84870403310     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-13-167     Document Type: Article

References (48)

1. U S Renal Data System, USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2009
2. Hospitalizations for valvular heart disease in chronic dialysis patients in the United States. Abbott KC, Agodoa LY, Nephron 2002 92 1 43 50 10.1159/000064476 12187083 (Pubitemid 34983874)
3. Hospitalizations for fungal infections after initiation of chronic dialysis in the United States. Abbott KC, Hypolite I, Tveit DJ, Hshieh P, Cruess D, Agodoa LY, Nephron 2001 89 4 426 432 10.1159/000046115 11721161 (Pubitemid 33135823)
4. Functional status of elderly adults before and after initiation of dialysis. Kurella Tamura M, Covinsky KE, Cherlow GM, Yaffe K, Landefeld S, McCulloch CE, N Engl J Med 2009 361 16 1539 1547 10.1056/NEJMoa0904655 19828531
5. Outcome and risk factors of ischemic heart disease in chronic uremia. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE, Kidney Int 1996 49 5 1428 1434 10.1038/ki.1996.201 8731110 (Pubitemid 26166417)
6. Elevated risk of stroke among patients with end-stage renal disease. Seliger SL, Gillen DL, Longstreth WT Jr, Kestenbaum B, Stehman-Breen CO, Kidney Int 2003 64 2 603 609 10.1046/j.1523-1755.2003.00101.x 12846756 (Pubitemid 36871932)
7. Chronic dialysis patients have high risk for pulmonary embolism. Tveit DP, Hypolite IO, Hshieh P, Cruess D, Agodoa LY, Welch PG, Abbott KC, Am J Kidney Dis 2002 39 5 1011 1017 10.1053/ajkd.2002.32774 11979344 (Pubitemid 34454219)
8. Changes in quality of life during hemodialysis and peritoneal dialysis treatment: generic and disease specific measures. Wu AW, Fink NE, Marsh-Manzi JV, Meyer KB, Finkelstein FO, Chapman MM, Powe NR, J Am Soc Nephrol 2004 15 3 743 753 10.1097/01.ASN.0000113315.81448.CA 14978177 (Pubitemid 38294805)
9. Cerebrovascular disease incidence, characteristics, and outcomes in patients initiating dialysis: the choices for healthy outcomes in caring for ESRD (CHOICE) study. Sozio SM, Armstrong PA, Coresh J, Jaar BG, Fink NE, Plantinga LC, Powe NR, Parekh RS, Am J Kidney Dis 2009 54 3 468 77 10.1053/j.ajkd.2009.01.261 19376618
10. The number, quality, and coverage of randomized controlled trials in nephrology. Strippoli GF, Craig JC, Schena FP, J Am Soc Nephrol: JASN 2004 15 2 411 419 10.1097/01.ASN.0000100125.21491.46 14747388 (Pubitemid 38140782)
11. Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. Agarwal R, Sinha AD, Hypertension 2009 53 5 860 866 10.1161/HYPERTENSIONAHA.108.128116 19273737
12. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. Cice G, Ferrara L, D'Andrea A, D'Isa S, Benedetto AD, Cittadini A, Russo PE, Golino P, Calabro R, J Am Coll Cardiol 2003 41 9 1438 1444 10.1016/S0735-1097(03)00241-9 12742278 (Pubitemid 36543357)
13. Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: any evidence of erythropoietin resistance? Cruz DN, Perazella MA, Abu-Alfa AK, Mahnensmith RL, Am J Kidney Dis 1996 28 4 535 540 10.1016/S0272-6386(96)90464-3 8840943 (Pubitemid 26337592)
14. Cardiac medications and their association with cardiovascular events in incident dialysis patients: cause or effect? Ishani A, Herzog CA, Collins AJ, Foley RN, Kidney Int 2004 65 3 1017 1025 10.1111/j.1523-1755.2004.00473.x 14871422 (Pubitemid 38251078)
15. Effect of angiotensin converting enzyme inhibitors and beta-blockers on left ventricular remodeling after coronary artery bypass graft surgery. Maruyama Y, Masaki N, Sato S, Kirimura M, Toyama K, Yuhara M, Sasaki O, Kamiyama T, Nishioka T, Ito H, Yoshimoto N, Int Heart J 2008 49 4 385 390 10.1536/ihj.49.385 18753722
16. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance. Saudan P, Halabi G, Perneger T, Wasserfallen JB, Wauters JP, Martin PY, Western Switzerland Dialysis Group, J Nephrol 2006 19 1 91 96 16523432
17. More than a decade of experience and still no consensus: controversies in iron therapy. Besarab A, Clin J Am Soc Nephrol: CJASN 2006 1 Suppl 1 1 3 17699371
18. Lost without directions: lessons from the anemia debate and the drive study. Spiegel DM, Chertow GM, Clin J Am Soc Nephrol: CJASN 2009 4 5 1009 1010 10.2215/CJN.00270109 19357246
19. Effective Health Care Program: About the DEcIDE Network http://effectivehealthcare.ahrq.gov/index.cfm/who-is-involved-in-the-effective- health-care-program1/about-the-decide-network/. Accessed August 24, 2012
20. Committee on Comparative Effectiveness Research Prioritization, Initial National Priorities for Comparative Effectiveness Research Washington, D.C: Institute of Medicine of the National Academies 2009
21. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ, JAMA 2004 291 451 9 10.1001/jama.291.4.451 14747502 (Pubitemid 38129749)
22. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink N, Martin A, Klag MJ, J Am Soc Nephrol 2002 13 7 1918 1927 10.1097/01.ASN.0000019641.41496.1E 12089389 (Pubitemid 34700618)
23. Both patient and facility contribute to achieving the Centers for Medicare and Medicaid Services' pay-for-performance target for dialysis adequacy. Tangri N, Tighiouart H, Meyer KB, Miskulin DC, J Am Soc Nephrol: JASN 2011 22 12 2296 2302 10.1681/ASN.2010111137 22025629
24. Computerized decision support for EPO dosing in hemodialysis patients. Miskulin DC, Weiner DE, Tighiouart H, Ladik V, Servilla K, Zager PG, Martin A, Johnson HK, Meyer KB, Am J Kidney Dis 2009 54 6 1081 1088 10.1053/j.ajkd.2009. 07.010 19781831
25. A computerized erythropoietin dosing algorithm improves anemia management and uses less erythropoietin. Miskulin DC, Weiner DE, Seefield K, Tighiouart H, Ladik V, Zager PG, Meyer K, J Am Soc Nephrol 2007 18 286A
26. Utilization and costs of cardiovascular disease medications in dialysis patients in medicare part D. Frankenfield DL, Weinhandl ED, Powers CA, Howell BL, Herzog CA, Peter WL, Am J Kidney Dis 2012 59 5 670 681 10.1053/j.ajkd.2011. 10.047 22206743
27. Development and validation of an electronic health record-based chronic kidney disease registry. Navaneethan SD, Jolly SE, Schold JD, Aarigain S, Saupe W, Sharp J, Lyons J, Simon JF, Schreiber MJ Jr, Jain A, Nally JV Jr, Clin J Am Soc Nephrol 2011 6 1 40 49 10.2215/CJN.04230510 21051745
28. Choices for healthy outcomes in caring for End stage renal disease. Powe NR, Klag MJ, Sadler JH, Anderson GF, Bass EB, Briggs WA, Fink NE, Levey AS, Levin NW, Meyer KB, Rubin HR, Wu AW, Semin Dial 1996 9 1 9
29. An improved comorbidity index for outcome analyses among dialysis patients. Liu J, Huang Z, Gilbertson DT, Foley RN, Collins AJ, Kidney Int 2010 77 141 151 10.1038/ki.2009.413 19907414
30. World Health Organization, International statistical classification of diseases and related health problems Geneva: World Health Organization 10 2004
31. US Renal Data System 2011 Annual Data Report, Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States http://www.usrds.org/ adr.aspx
32. Developing a health-related quality-of-life measure for end-stage renal disease: the CHOICE health experience questionnaire. Wu AW, Fink NE, Cagney KA, Bass EB, Rubin HR, Meyer KB, Sadler JH, Powe NR, Am J Kidney Dis 2001 37 1 11 21 11136162 (Pubitemid 32055013)
33. The central role of the propensity score in observational studies for causal effects. Rosenbaum PR, Rubin DB, Biometrika 1983 70 1 42 55
34. Estimation of causal effects using propensity score weighting: an application to data on right heart catheterization. Hirano K, Imbens GW, Health Serv Outcomes Res Methodology 2001 2 259 278 10.1023/A:1020371312283
35. Marginal structural models to estimate the joint effect of non randomized treatments. Hernán MA, Brumback B, Robins JM, J Am Stat Assoc 2001 96 440 448 10.1198/016214501753168154 (Pubitemid 33283729)
36. Longitudinal data analysis using generalized linear models. Liang KY, Zeger SL, Biometrika 1986 73 1 13 22 10.1093/biomet/73.1.13
37. Diggle PJ, Heagerty P, Liang K-Y, Zeger S, Analysis of Longitudinal Data Oxford: OUP 2 2002
38. Regression analysis of grouped survival data with application to breast cancer data. Prentice RL, Gloeckler LA, Biometrics 1978 34 57 67 10.2307/2529588 630037 (Pubitemid 8316897)
39. Issues regarding 'immortal time' in the analysis of the treatment effects in observational studies. Liu J, Weinhandl ED, Gilbertson DT, Collins AJ, Peter WL, Int Soc Nephrol 2012 81 341 350
40. Comparing different strategies for timing of dialysis initiation through inverse probability weighting. Sjölander A, Nyrén O, Bellocco R, Am J Epidemiol 2011 174 1204 1210 10.1093/aje/kwr249 21984655
41. Variation in fistula use across dialysis facilities: is it explained by case-mix? Tangri N, Moorthi R, Tighiouhart H, Meyer KB, Miskulin DC, Clin J Am Soc Nephrol: CJASN 2010 5 2 307 313 10.2215/CJN.04430709 20056763
42. Early start of hemodialysis may be harmful. Rosansky SJ, Eggers P, Jackson K, Glassock R, Clark WF, Arch Intern Med 2011 171 5 396 403 10.1001/archinternmed.2010.415 21059968
43. Initiation of dialysis at higher GFRs: is the apparent rising tide of early dialysis harmful or helpful? Rosansky SJ, Clark WF, Eggers P, Glassock RJ, Kidney Int 2009 76 3 257 61 10.1038/ki.2009.161 19455195
44. Frailty, dialysis initiation, and mortality in end-stage renal disease. Bao Y, Dalrymple L, Chertow GM, Kaysen GA, Johansen KL, Arch Intern Med 2012 172 14 1071 7 10.1001/archinternmed.2012.3020 22733312
45. Outcomes of patients with delayed dialysis initiation: results from the AVENIR study. Thilly N, Boini S, Soudant M, Briancon S, Frimat L, Am J Nephrol 2011 33 1 76 83 10.1159/000322835 21178337
46. Timing of dialysis initiation and survival in ESRD. Wright S, Klausner D, Baird B, Williams ME, Steinman T, Tang H, Ragasa R, Goldfarb-Rumyantzev AS, Clin J Am Soc Nephrol 2010 5 10 1828 1835 10.2215/CJN.06230909 20634325
47. Comparing different strategies for timing of dialysis initiation through inverse probability weighting. Sjölander A, Nyrén O, Bellocco R, Evans M, Am J Epidemiol 2011 174 10 1204 10 10.1093/aje/kwr249 21984655
48. Centers for Medicare and Medicaid Services, End Stage Renal Disease (ESRD) Quality Improvement Initiative 2012 http://www.cms.gov/Medicare/End- Stage-Renal-Disease/ESRDQualityImproveInit/index.html. Accessed September 9, 2012